This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Griffin, K. A Articles by Bidani, A. K Search for Related Content PubMed Articles by Griffin, K. A Articles by Bidani, A. K Social Bookmarking                         What's this?

Relative antihypertensive and glomeruloprotective efficacies of enalapril and candesartan cilexetil in the remnant kidney model

Department of Medicine, Loyola University Medical Center and Hines VA Hospital, prado@research. hines.med.va.gov

Maria M Picken

Pathology, Loyola University Medical Center and Hines VA Hospital, Maywood, IL USA

George Bakris

Department of Preventive Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA

Anil K Bidani

Department of Medicine, Loyola University Medical Center and Hines VA Hospital

The present studies were performed to investigate whether the differences described between the two modalities for interruption of the renin-angiotensin-aldosterone system (RAAS), angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin AT ₁receptor antagonists (AIIA) result in differences in renoprotective efficacy in the rat remnant kidney model. Male Sprague-Dawley rats with an initial body weight of 225—300 g, underwent 5/6 renal ablation and had radiotransmitters installed for radiotelemetric blood pressure (BP) measurements, owing to the known limitations of periodic tail-cuff BP measurements to adequately reflect ambient BP profiles. After renal ablation surgery, the rats received no treatment (n=10); enalapril (n=11) or candesartan (n=9) after the first week, both administered initially at a dose of 50 mg/l of drinking water (~10 mg/kg). However, the dose of candesartan had to be reduced to 10—25 mg/l in 4/9 rats to avoid excessive hypotension. Both enalapril and candesartan produced significant reductions in average systolic BP during the subsequent approximately six weeks of observations as compared with untreated rats (187±4 mmHg, p<0.001), but candesartan was significantly more effective at these relative doses (121±3 vs. 133±4 mmHg, p<0.05). At approximately seven weeks, serum creatinine and proteinuria were measured before sacrifice for morphologic assessment of percentage glomerulosclerosis (GS). Despite the described differences between ACE-I and AIIA after acute administration, the percentage GS was reduced similarly by enalapril (down to 6.8±2.8%) and candesartan (down to 2.9±1.5%) as compared with untreated rats (37.2±4.3%). Moreover, GS in individual animals paralleled the BP reductions achieved. Proteinuria was reduced in parallel to the decrease in % GS. These data indicate that, at least in the 5/6 renal ablation model, RAAS blockade by either ACE-I or AIIA provides protection by BPdependent rather than BP-independent mechanisms. This may reflect the primarily hypertensive pathogenesis of GS in this model, and the fact that hypertension is also very angiotensin II-dependent in this model. Thus, these data suggest that models other than the 5/6 ablation model may be more appropriate to demonstrate the BP-independent protective effects of RAAS blockade.

Key Words: experimental hypertension • remnant kidney • glomerulosclerosis • angiotensin II receptor antagonist • angiotensin-converting enzyme inhibitor

References

• Brenner BM Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324-F337.[Web of Science][Medline] [Order article via Infotrieve]
• Bidani AK, Schwartz MM, Lewis EJ Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987;252:F1003-F1010.[Web of Science][Medline] [Order article via Infotrieve]
• Klahr S., Schreiner G., Ichikawa I. The progression of renal disease. N Eng J Med 1988;318:1657-66.[Abstract]
• Olson JL, Heptinstall RH Non-immunologic mechanisms of glomerular injury. Lab Invest 1988;59:564-78.[Web of Science][Medline] [Order article via Infotrieve]
• Fogo A., Ichikawa I. Evidence of central role of glomerular growth promoters in the development of sclerosis. Semin Nephrol 1990;9:329-42.[Web of Science]
• Neuringer JR, Brenner BM Hemodynamic theory of progressive renal disease: a 10-year update in brief review. Am J Kidney Disease 1993;22:98-104.[Web of Science][Medline] [Order article via Infotrieve]
• Ketteler M., Noble NA, Border WA Transforming growth factor-β and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 1995;57:279-295.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Striker GE, He CJ, Liu ZH et al. Biology of disease. Pathogenesis of nonimmune glomerulosclerosis: Studies in animals and potential applications to humans. Lab Invest 1995;73:596-605.[Web of Science][Medline] [Order article via Infotrieve]
• Remuzzi G., Ruggenenti P., Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.[Web of Science][Medline] [Order article via Infotrieve]
• Anderson S., Rennke HG, Brenner BM Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.[Web of Science][Medline] [Order article via Infotrieve]
• Lafayette RA, Mayer G., Park SK, Meyer TW Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-71.[Web of Science][Medline] [Order article via Infotrieve]
• Griffin KA, Picken M., Bidani AK Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 1994;46:1010-18.[Web of Science][Medline] [Order article via Infotrieve]
• Griffin KA, Picken MM, Bidani AK Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995;96:793-800.[Web of Science][Medline] [Order article via Infotrieve]
• Ots M., Mackenzie HS,Troy JL, Rennke HG, Brenner BM Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998;9:224-30.[Abstract]
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
• Maschio G., Alberti D., Janin G. et al. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.[Abstract/Free Full Text]
• Kakinuma Y., Kawamura T., Bills T., Yoshioka T., Ichikawa I., Fogo A. Blood pressure-independent effect of angiotensin inhibition on glomerular and non-glomerular vascular lesions of chronic renal failure. Kidney Int 1992;42:46-55.[Web of Science][Medline] [Order article via Infotrieve]
• Matsusaka T., Hymes J., Ichikawa I. Angiotensin in progressive renal disease: Theory and practice. J Am Soc Nephrol 1996;7:2025-43.[Abstract]
• Kon V., Fogo A., Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-50.[Web of Science][Medline] [Order article via Infotrieve]
• Dzau VJ, Sasamura H., Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11:S13-S18.
• Nakajima M., Hutchinson HG, Fujinaga M. et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. J Clin Invest 1995;92:10663-7.
• Bidani AK, Griffin KA, Picken M., Lansky DM Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol 1993;265:F391-F398.[Web of Science][Medline] [Order article via Infotrieve]
• Griffin KA, Picken MM, Bakris GL, Bidani AK Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999;55:1849-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bidani AK, Picken MM, Bakris G., Griffin KA Lack of evidence of BP independent protection by renin-angiotensin system blockade after renal ablation. KidneyInt 2000;57:1651-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wallenstein SC, Zucker CL, Fleiss JL Some statistical methods useful in circulation research. Circ Res 1980;47:1-9.[Abstract/Free Full Text]
• Parati G., Ombon S., Dirienzo M., Frattola A., Albini F., Mancia G. Twenty-four hour blood pressure variability: Clinical implications. Kidney Int 1992;41:S24-S28.[CrossRef][Web of Science]
• Holstein-Rathlou NH, He J., Wagner AJ, Marsh DJ Patterns of blood pressure variability in normotensive and hypertensive rats. Am J Physiol 1995;269:F1230-F1239.
• Persson PB Modulation of cardiovascular control mechanisms and their interaction. Physiol Rev 1996;76:193-244.[Abstract/Free Full Text]
• Pelayo JC, Westcott JY Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant kidney nephron. J Clin Invest 1991;88:101-5.[Web of Science][Medline] [Order article via Infotrieve]
• Morsing P. Candesartan. A new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. J Am Soc Nephrol 1999;10:S248-S254.[Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl, S191-S195 (2001)
DOI: 10.1177/14703203010020013301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Griffin, K. A Articles by Bidani, A. K Search for Related Content PubMed Articles by Griffin, K. A Articles by Bidani, A. K Social Bookmarking                         What's this?